{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005498","form_type":"8-K","ticker":"EDAP","cik":"0001041934","company_name":"EDAP TMS SA","filed_at":"2026-08-13T20:02:17+00:00","discovered_at":"2026-08-13T20:03:01.103681+00:00","generated_at":"2026-08-13T20:03:23.883425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FocalTherics Q2 revenue up 39% to $13.2M; net loss widens; $40M offering","bullets":["Revenue $13.2M, +39% YoY; U.S. procedure volume +47%; 13 Focal One systems sold vs 9.","Gross margin 55.6% vs 51.1%; operating loss $8.0M vs $6.6M; net loss $14.4M ($0.38/sh) vs $6.4M.","ESWL and Distribution reclassified as discontinued operations; HIFU now only continuing ops; cash $21.5M.","FY2026 revenue guidance reaffirmed $50-54M (34-45% growth); $40M public offering expected to close Aug 14.","Launched first commercial Focal One Endometriosis program in Europe; installed base 184 (96 U.S.)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005498","json":"https://secwatch.observer/filing/0001171843-26-005498.json","markdown":"https://secwatch.observer/filing/0001171843-26-005498.md","text":"https://secwatch.observer/filing/0001171843-26-005498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041934/000117184326005498/0001171843-26-005498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041934/000117184326005498/f8k_081326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:03:23.883425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}